Last reviewed · How we verify
antihypertensive drugs
At a glance
| Generic name | antihypertensive drugs |
|---|---|
| Also known as | Thiazide diuretics and ACE inhibitor and β-blocker, labipress |
| Sponsor | Mei changlin |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Nutritional Ketosis Marfan (NA)
- CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension (NA)
- Effect of Hypertensive Drugs on Root Caries Among Senior Patients in Cairo University
- Orthostatic And Postprandial Hypotension In Hospitalized Older Adults (HOPE65)
- Use of a Cloud-connected Remote Blood Pressure Monitoring Program During the Postpartum Period for Hypertensive Women
- CENtral Blood Pressure Targeting: A Pragmatic RAndomized Pilot triaL in Advanced Chronic Kidney Disease (NA)
- BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT (NA)
- REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- antihypertensive drugs CI brief — competitive landscape report
- antihypertensive drugs updates RSS · CI watch RSS
- Mei changlin portfolio CI